Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Antitumor agent
BML-L108-0005 5 mg 75.00 USD
BML-L108-0025 25 mg 318.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: ALX-300-004

Produces strong antitumor and antimetastatic activities. Inhibits phosphatidylinositol specific phospholipase C (PLC, IC50=0.4-9.6μM) and protein kinase C from various leukemic cells. Inhibits CoA-independent transacylase (IC50=0.5μM). Induces apoptosis in HeLa cells and HL-60 cells. Antineoplastic activity.

Product Specification

Alternative Name:2-O-Methyl-PAF-C-18, sn-ET-18-OCH3, Edelfosine
Purity:≥98% (TLC)
Identity:Determined by FAB-MS.
Appearance:White waxy solid.
Solubility:Soluble in 100% ethanol (15mg/ml), DMSO or dimethyl formamide.
Long Term Storage:-20°C
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C.
Please mouse over

Product Literature References

Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis: C. Gajate, et al.; Int. J. Cancer 85, 674 (2000), Abstract;
Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells: C. Gajate, et al.; Int. J. Cancer 86, 208 (2000), Abstract;
Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis: G.A. Ruiter, et al.; Cancer Res. 59, 2457 (1999), Abstract;
Induction of apoptosis in human mitogen-activated peripheral blood T- lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system: C. Cabaner, et al.; Br. J. Pharmacol. 127, 813 (1999), Abstract;
Liposomal ET-18-OCH(3) induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling: O. Cuvillier, et al.; Blood 94, 3583 (1999), Abstract;
Apoptosis triggered by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine is prevented by increased expression of CTP:phosphocholine cytidylyltransferase: I. Baburina & S. Jackowski; J. Biol. Chem. 273, 2196 (1998), Abstract;
Cytotoxic etherphospholipid analogues: D. Berkovic; Gen Pharmacol. 31, 511 (1998), Abstract;
Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O- methyl-rac-glycero-3-phosphocholine: C. Gajate, et al.; Mol. Pharmacol. 53, 602 (1998), Abstract;
The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo: W.R. Vogler, et al.; Cancer Invest. 16, 549 (1998), Abstract;
The inhibition of cell signaling pathways by antitumor ether lipids: G. Arthur & R. Bittman; Biochim. Biophys. Acta. 1390, 85 (1998), Abstract;
Ether lipids enhance the cytotoxic effect of teniposide and paclitaxel in liposomes against leukaemic cells in culture: B.B. Lundberg; Anticancer Drug Des. 12, 503 (1997), Abstract;
Selective induction of apoptosis in cancer cells by the ether lipid ET- 18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L): F. Mollinedo, et al.; Cancer Res. 57, 1320 (1997), Abstract;
Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 : J.D. Winkler, et al.; J. Pharmacol. Exp. Ther. 279, 956 (1996), Abstract;
The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells: F. Mollinedo, et al.; Biochem. J. 302, 325 (1994), Abstract;
Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3: F. Mollinedo, et al.; Biochem. Biophys. Res. Commun. 192, 603 (1993), Abstract;
Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues: G. Powis, et al.; Cancer Res. 52, 2835 (1992), Abstract;
HL-60 cells become resistant towards antitumor ether-linked phospholipids following differentiation into a granulocytic form: D.S. Vallari, et al.; BBRC 156, 1 (1988), Abstract;
Purging leukemic cells from simulated human remission marrow with alkyl- lysophospholipid: S. Okamoto, et al.; Blood 69, 1381 (1987), Abstract;
Phospholipid-sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl- lysophospholipid: D.M. Helfman, et al.; Cancer Res. 43, 2955 (1983), Abstract;
Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids: M. Modolell, et al.; Cancer Res. 39, 4681 (1979), Abstract;
Selective destruction of human leukemic cells by alkyl- lysophospholipids: R. Andreesen, et al.; Cancer Res. 38, 3894 (1978), Abstract;

Related Literature

Technical Posters
Arachidonic Acid Metabolites
Arachidonic Acid Metabolites
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,